Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Curaleaf Holdings, Inc. (CURLF)
USD10.06
+0.60 (+6.34%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
290 Harbor Drive 6902
Stamford, CT, US
Stamford, CT, US
CEO
Boris Alexis Jordan
Website
curaleaf.com
IPO
2018-10-29
CIK 1756770 ISIN CA23126M1023
Also trades on
Canadian Securities Exchange · CURA.CN (CAD)
Other OTC · CURLF (USD)
Toronto Stock Exchange · CURA.TO (CAD)
Description
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.06
+0.60 (+6.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
454.9K
Beta
1.43
Float Shares
490.22M
Free Float %
62.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.26% | -1.03% | +65.67% | +62.18% | +38.85% | +53.17% | +369.82% | +56.59% | -73.45% | -34.02% | -34.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
10.06
Low
6.25
-37.9%
Consensus
13.02
+29.4%
Median
11.75
+16.8%
High
23.87
+137.3%
DCF (Levered)
1.63
-83.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 10 |
13.29
+32.1%
|
Quality scores
Altman Z-Score
0.76
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.9% Q1'26: +3.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-6.9% Q1'26: +208.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.3% Q1'26: +1.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+1.8% Q1'26: +0.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.3% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.3% Q1'26: +4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.20× Q1'26: 7.69× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
73.13M
est: 94.23M (-22.4%)
|
226.16M
est: 220.30M (+2.7%)
|
659.74M
est: 634.72M (+3.9%)
|
1.19B
est: 1.21B (-2.2%)
|
1.22B
est: 1.34B (-8.8%)
|
1.37B
est: 1.34B (+2.0%)
|
1.28B
est: 1.34B (-4.9%)
|
1.29B
est: 1.27B (+1.2%)
|
1.34B
1.33B – 1.36B
+5.1% YoY
|
1.45B
1.34B – 1.50B
+8.1% YoY
|
1.59B
1.53B – 1.63B
+9.8% YoY
|
1.73B
1.67B – 1.78B
+8.9% YoY
|
1.88B
1.81B – 1.93B
+8.3% YoY
|
| EBITDA |
-38.22M
est: 16.15M (-336.7%)
|
16.55M
est: 37.75M (-56.2%)
|
188.99M
est: 108.75M (+73.8%)
|
148.56M
est: 207.76M (-28.5%)
|
161.34M
est: 230.15M (-29.9%)
|
191.38M
est: 230.40M (-16.9%)
|
221.95M
est: 207.65M (+6.9%)
|
166.88M
est: 196.97M (-15.3%)
|
207.09M
205.54M – 210.18M
+5.1% YoY
|
223.89M
206.90M – 231.61M
+8.1% YoY
|
245.90M
237.01M – 252.18M
+9.8% YoY
|
267.84M
258.16M – 274.68M
+8.9% YoY
|
290.12M
279.63M – 297.53M
+8.3% YoY
|
| EBIT |
-46.43M
est: 2.72M (-1,807.6%)
|
-21.53M
est: 6.36M (-438.6%)
|
105.07M
est: 18.31M (+473.7%)
|
16.17M
est: 34.99M (-53.8%)
|
2.26M
est: 38.76M (-94.2%)
|
-24.42M
est: 38.80M (-162.9%)
|
-16.20M
est: 763.5K (-2,221.4%)
|
23.01M
est: 724.2K (+3,077.4%)
|
761.4K
755.7K – 772.8K
+5.1% YoY
|
823.2K
760.7K – 851.6K
+8.1% YoY
|
904.1K
871.4K – 927.2K
+9.8% YoY
|
984.8K
949.2K – 1.01M
+8.9% YoY
|
1.07M
1.03M – 1.09M
+8.3% YoY
|
| Net Income |
-53.59M
est: -92.60M (+42.1%)
|
-68.81M
est: -89.96M (+23.5%)
|
-60.18M
est: -50.03M (-20.3%)
|
-204.13M
est: -109.54M (-86.4%)
|
-355.43M
est: -131.64M (-170.0%)
|
-286.35M
est: -228.63M (-25.2%)
|
-226.73M
est: -200.33M (-13.2%)
|
-235.12M
est: -222.02M (-5.9%)
|
-70.87M
-146.16M – -8.86M
+68.1% YoY
|
-135.44M
-203.16M – -74.49M
-91.1% YoY
|
-23.62M
-24.41M – -22.51M
+82.6% YoY
|
39.37M
37.52M – 40.68M
+266.7% YoY
|
94.49M
90.05M – 97.63M
+140.0% YoY
|
| SGA |
64.01M
est: 33.46M (+91.3%)
|
140.83M
est: 78.22M (+80.0%)
|
271.79M
est: 225.37M (+20.6%)
|
422.37M
est: 430.56M (-1.9%)
|
430.15M
est: 476.96M (-9.8%)
|
442.76M
est: 477.46M (-7.3%)
|
425.75M
est: 464.88M (-8.4%)
|
472.30M
est: 440.96M (+7.1%)
|
463.61M
460.15M – 470.53M
+5.1% YoY
|
501.23M
463.21M – 518.52M
+8.1% YoY
|
550.51M
530.62M – 564.57M
+9.8% YoY
|
599.62M
577.96M – 614.94M
+8.9% YoY
|
649.50M
626.03M – 666.09M
+8.3% YoY
|
| EPS |
-0.16
est: -0.13 (-28.0%)
|
-0.15
est: -0.12 (-23.5%)
|
-0.11
est: -0.07 (-62.9%)
|
-0.16
est: -0.15 (-8.2%)
|
-0.53
est: -0.18 (-198.3%)
|
-0.40
est: -0.31 (-29.6%)
|
-0.29
est: -0.25 (-14.0%)
|
-0.31
est: -0.28 (-9.9%)
|
-0.09
-0.19 – -0.01
+68.1% YoY
|
-0.17
-0.26 – -0.09
-91.1% YoY
|
-0.03
-0.03 – -0.03
+82.6% YoY
|
0.05
0.05 – 0.05
+266.7% YoY
|
0.12
0.11 – 0.12
+140.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
43.87M
OE per share TTM
0.06
Owner's Yield
1.49%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
63.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
162.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-1 vs prev Q
New positions
1
Closed positions
2
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ALBERT D MASON INC | 75.1K -1.9K (-2.5%) | 160.7K -33.3K (-17.2%) | 0.01% 0.000 pp | 0.10% -0.024 pp | USD7.29 -70.6% | 19 qtrs — |
| 2 | GOLDEN STATE EQUITY PARTNERS | 600.00 +600.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.14 +0.0% | 1 qtrs NEW |
| 3 | NBC SECURITIES, INC. | 22.00 +— (+0.0%) | 47.00 -8.0 (-14.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.77 -22.7% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
4.1K
Shares Outstanding
781.75M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Boris Alexis Jordan | Chief Executive Officer & Chairman | 2M | male |
| Matthew S. Darin | Special Advisor | 1M | male |
| Edward Kremer | Chief Financial Officer | 882.8K | male |
| Joseph F. Lusardi | Executive Vice-Chairman | 802.5K | male |
| Peter Laurence Clateman | Chief Legal Officer | 667.9K | male |
| Camilo Russi Lyon | Chief Investment Officer | 542.9K | male |
| Helen Chen | Senior Vice President of Digital | — | female |
| Daniel Mickelson | Chief Accounting Officer | — | male |
| Rahul Pinto | President | — | male |
| Scott Baughman | Chief Technology Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CURLF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
